Eugenol prevents Angiotensin II-induced premature senescence in vascular tissues and human vascular smooth muscle cells by downregulating MFG-E8 expression.
Does eugenol prevent Angiotensin II-induced vascular smooth muscle cell senescence?
Eugenol prevents Angiotensin II-induced aging in vascular smooth muscle cells and vascular tissues by downregulating MFG-E8 expression, suggesting potential as an antiaging therapy.
ABSTRACT The biological aging of vascular smooth muscle cells (VSMCs) is a critical event contributing to vascular aging and age‐related diseases. The objective of this study is to assess the potential mechanism by which eugenol inhibits vascular senescence by downregulating milk fat globule‐EGF factor 8 (MFG‐E8) expression in VSMCs and vascular tissues. A model of angiotensin II (Ang II)‐induced vascular aging in mice and a premature aging model in human vascular smooth muscle cells (HVSMCs) were established to assess the efficacy of eugenol intervention, with valsartan, an Ang II receptor antagonist, serving as a positive control drug. Senescence‐associated‐β‐galactosidase (SA‐β‐gal) staining, along with the detection of senescence marker molecules p21 and p53, were used to assess the senescence status of cells and vascular tissues. The expression level of MFG‐E8 was detected using immunohistochemistry, reverse transcription‐quantitative PCR, and western blot analysis. HVSMC cell lines with MFG‐E8 knockdown and overexpression were generated using short hairpin RNA and plasmid overexpression methods, respectively, to assess the role of MFG‐E8 in the anti‐senescence effects of eugenol on VSMCs. Eugenol inhibited Ang II‐induced premature senescence in both vascular tissues and HVSMCs, significantly enhancing arterial stiffness and structural changes in aged vessels. It also attenuated the senescence‐associated secretory phenotype (SASP) and enhanced the proliferative activity of senescent VSMCs. Ang II exposure led to increased MFG‐E8 expression in cells and vascular tissues, a change that eugenol was able to reverse. Knockdown of MFG‐E8 suppressed the Ang II‐induced senescence phenotype in HVSMCs, whereas overexpression of MFG‐E8 directly induced HVSMC senescence and counteracted the anti‐aging effects of eugenol. Eugenol prevents Ang II‐induced aging in VSMCs and vascular tissues by downregulating MFG‐E8 expression, underscoring its potential as an antiaging drug.
He et al. (Sun,) conducted a other in Vascular aging. Eugenol vs. Valsartan (positive control) / Ang II alone was evaluated on Senescence status (SA-β-gal staining, p21, p53) and MFG-E8 expression. Eugenol prevents Angiotensin II-induced premature senescence in vascular tissues and human vascular smooth muscle cells by downregulating MFG-E8 expression.